Monte Rosa Therapeutics
IPO
Degrading proteins, making medicines
- Headquarters
- Boston, Massachusetts
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- monterosatx.com
- Total Funding
- $127.5M
- Last Round
- $95.0M Series CMar 2021
About
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines that reprogram ubiquitin ligases to eliminate disease-driving proteins previously considered undruggable. The company's proprietary platform integrates MGD chemistry, AI, structural biology, and proteomics to advance programs targeting cancer and other serious diseases.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account